Skip to content

High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors

High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02035852
Enrollment
184
Registered
2014-01-14
Start date
2009-08-28
Completion date
2018-04-20
Last updated
2019-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor

Brief summary

The study will compare two different size MRI's of a brain tumor.

Detailed description

The study is designed to directly compare the MR images of a brain tumor obtained on the 3T and then 7T MRI in approximately 150 patients followed serially with MR imaging to evaluate for tumor progression.

Interventions

OTHERMRI

3T MRI vs. 7T MRI

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, age 18 years or older * Patient must meet at least one of the four following criteria regarding brain tumor diagnosis: * Histological diagnosis of a brain tumor * Histological diagnosis of systemic cancer and brain MR imaging suggestive of metastatic disease to the brain * Pre-operative brain MR imaging suggestive of a brain tumor * Radiographic diagnosis of brain tumor in an inoperable location (e.g., brainstem) * Patient able and willing to provide informed consent * Karnofsky Performance status \> 70% * Life expectancy greater than 3 months * Negative serum or urine pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control * Patients who are excluded from 7T MR imaging because of titanium implants that are not yet established to be safe at 7T remain eligible for the imaging at 3T \* Spanish speaking participants will be enrolled for this study

Exclusion criteria

* Body weight \>137 Kg (300 lbs) * Patient unable to provide informed consent * Karnofsky Performance status \< 70% * Patients who are claustrophobic or have other contraindications to MRI, such as implanted pacemaker device vascular clips, surgical clips, prosthetic valves, pacemakers, otologic implants * NYHA class III and IV congestive heart failure * Psychiatric or addictive disorders that preclude obtaining informed consent * Unstable angina * Sexually active patients of childbearing potential not using a reliable contraceptive method * Pregnant or lactating women * Women of childbearing potential who refuse a pregnancy test (performed during screening)

Design outcomes

Primary

MeasureTime frameDescription
Benefit of 7T MR imagingBaseline and 6 month intervals after baseline1\. To determine the benefit of 7T MR imaging in brain tumor patients with regard to the improvement in resolution, as measured by the area of T2 FLAIR signal abnormality and the ability to detect abnormalities in vascular integrity. The benefit will be determined at a single time point as well as longitudinally for each patient at 6 month intervals.

Secondary

MeasureTime frameDescription
Vascular IntegrityEvery 6 months, up to 12 months.To determine if changes in vascular integrity at 7T can be correlated with tumor progression or transformation to high grade in patients with low grade gliomas.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026